BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 10210218)

  • 1. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
    Delbeke D
    J Nucl Med; 1999 Apr; 40(4):591-603. PubMed ID: 10210218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of (18)F-FDG in oncology.
    Nabi HA; Zubeldia JM
    J Nucl Med Technol; 2002 Mar; 30(1):3-9; quiz 10-1. PubMed ID: 11948260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical role of positron emission tomography in oncology.
    Bomanji JB; Costa DC; Ell PJ
    Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
    Macapinlac HA
    Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG PET and PET/CT imaging in lymphoma and melanoma.
    Macapinlac HA
    Cancer J; 2004; 10(4):262-70. PubMed ID: 15383207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effective PET scans in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
    Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Positron-emission tomography in oncology].
    Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
    Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
    Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
    Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of PET in oncology.
    Rohren EM; Turkington TG; Coleman RE
    Radiology; 2004 May; 231(2):305-32. PubMed ID: 15044750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis of colorectal cancer with FDG-PET].
    Uno K
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():168-72. PubMed ID: 14574875
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cost-effective PET investigations in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
    Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Positron emission tomography (PET) in clinical oncology. Part II].
    Cabrera Villegas A; Gámez Cenzano C; Martín Urreta JC
    Rev Esp Med Nucl; 2002 Apr; 21(2):131-47; quiz 149-51. PubMed ID: 11879626
    [No Abstract]   [Full Text] [Related]  

  • 13. The applications of PET in clinical oncology.
    Strauss LG; Conti PS
    J Nucl Med; 1991 Apr; 32(4):623-48; discussion 649-50. PubMed ID: 2013803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography imaging of colorectal cancer.
    Akhurst T; Larson SM
    Semin Oncol; 1999 Oct; 26(5):577-83. PubMed ID: 10528907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Colorectal cancer].
    Ito K; Kato T
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):270-7. PubMed ID: 12073633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
    Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
    Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET in oncology: will it replace the other modalities?
    Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
    Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
    Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
    Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
    Kostakoglu L; Goldsmith SJ
    J Nucl Med; 2003 Feb; 44(2):224-39. PubMed ID: 12571214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
    Czech N; Brenner W; Kampen WU; Henze E
    Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.